Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BHC 
Bausch Health Companies Inc (BHC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: BHC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -24.15% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.39B USD | Price to earnings Ratio - | 1Y Target Price 8.67 |
Price to earnings Ratio - | 1Y Target Price 8.67 | ||
Volume (30-day avg) 1834855 | Beta 0.6 | 52 Weeks Range 3.96 - 11.46 | Updated Date 03/31/2025 |
52 Weeks Range 3.96 - 11.46 | Updated Date 03/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.13 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -0.48% | Operating Margin (TTM) 23.21% |
Management Effectiveness
Return on Assets (TTM) 4.33% | Return on Equity (TTM) -2304.54% |
Valuation
Trailing PE - | Forward PE 1.43 | Enterprise Value 22823777081 | Price to Sales(TTM) 0.25 |
Enterprise Value 22823777081 | Price to Sales(TTM) 0.25 | ||
Enterprise Value to Revenue 2.37 | Enterprise Value to EBITDA 8.09 | Shares Outstanding 367934016 | Shares Floating 275236631 |
Shares Outstanding 367934016 | Shares Floating 275236631 | ||
Percent Insiders 11.31 | Percent Institutions 70.95 |
Analyst Ratings
Rating 3.17 | Target Price 9.5 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 4 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Bausch Health Companies Inc
Company Overview
History and Background
Bausch Health Companies Inc., formerly known as Valeant Pharmaceuticals, was founded in 1853 as Bausch & Lomb. It evolved from an optical products company to a pharmaceutical company through strategic acquisitions and restructuring. The company faced significant challenges, including debt accumulation and controversies, leading to a rebranding to Bausch Health.
Core Business Areas
- Bausch + Lomb: This segment focuses on vision care, including contact lenses, lens care products, and ophthalmic pharmaceuticals.
- Salix Pharmaceuticals: Salix develops and markets gastrointestinal products such as Xifaxan and Relistor.
- International Pharmaceuticals: This segment includes a broad range of pharmaceutical products sold outside the U.S. and Canada.
Leadership and Structure
The company is led by Thomas Appio (CEO). The organizational structure includes distinct business units focused on specific therapeutic areas and geographical regions.
Top Products and Market Share
Key Offerings
- Xifaxan: Xifaxan is a gastrointestinal drug used to treat irritable bowel syndrome with diarrhea (IBS-D) and hepatic encephalopathy. Competitors include generics and other IBS-D treatments. Revenue figures can be found in the company's SEC filings. Market share data is available from pharmaceutical market research reports.
- Lotemax: Lotemax is a corticosteroid indicated for inflammatory eye conditions and post-operative inflammation. Market share data is available from pharmaceutical market research reports. Competitors include Durezol, Flarex, and other ophthalmic corticosteroids.
- Bausch + Lomb ULTRA: Bausch + Lomb ULTRA is a monthly replacement contact lens. Competitors include Acuvue, Air Optix, and Dailies. Market share and revenue data can be found from vision care industry market reports and company SEC filings.
Market Dynamics
Industry Overview
The pharmaceutical and vision care industries are characterized by intense competition, regulatory scrutiny, and the need for continuous innovation. The industries are experiencing growth driven by an aging population and increasing healthcare spending.
Positioning
Bausch Health holds a significant position in the gastrointestinal and vision care markets. Its competitive advantages include established brands and a diversified product portfolio.
Total Addressable Market (TAM)
The TAM for Bausch Health's segments (GI and vision care) is estimated to be in the tens of billions of dollars. Bausch Health is positioned to capture a portion of this market through its established brands and pipeline of new products.
Upturn SWOT Analysis
Strengths
- Established brands (e.g., Xifaxan, Lotemax)
- Diversified product portfolio
- Global presence
- Strong distribution network
Weaknesses
- High debt levels
- Past controversies affecting reputation
- Exposure to generic competition
- Dependence on key products
Opportunities
- New product development and launches
- Expansion into emerging markets
- Strategic acquisitions and partnerships
- Growing demand for vision care and GI products
Threats
- Generic competition
- Regulatory changes
- Pricing pressures
- Economic downturns impacting healthcare spending
Competitors and Market Share
Key Competitors
- JNJ
- PFE
- ABBV
- MRK
- ALVR
Competitive Landscape
Bausch Health faces intense competition from both branded and generic drug manufacturers. Its competitive advantages include its established brands and focused product portfolio, but its high debt levels remain a disadvantage.
Major Acquisitions
Acquired Company Name
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Example Strategic Rationale: Expanded product portfolio in dermatology.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been impacted by divestitures and restructuring efforts. Revenue growth has been inconsistent due to patent expirations and competition.
Future Projections: Future growth projections depend on successful new product launches, deleveraging efforts, and market conditions. Analyst estimates can be found on financial data platforms.
Recent Initiatives: Recent strategic initiatives include debt reduction, streamlining operations, and focusing on core business segments.
Summary
Bausch Health is a company undergoing a significant turnaround, marked by a focus on core businesses and debt reduction. Its established brands in vision care and gastroenterology provide a solid foundation. However, high debt and generic competition pose ongoing challenges. Successful execution of strategic initiatives is crucial for sustained growth and shareholder value.
Similar Companies
- JNJ
- PFE
- ABBV
- MRK
- ALVR
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Financial Data Platforms (e.g., Yahoo Finance, Bloomberg)
- Pharmaceutical Market Research Reports
- Vision Care Industry Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bausch Health Companies Inc
Exchange NYSE | Headquaters Laval, QC, Canada | ||
IPO Launch date 1994-03-29 | CEO & Director Mr. Thomas J. Appio | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 20700 | Website https://www.bauschhealth.com |
Full time employees 20700 | Website https://www.bauschhealth.com | ||
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; dermatology products; generic pharmaceutical products; and dentistry products. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.